

2025-02-28
Press invitation

Replay Link to Digital Press Briefing – March 5, 2025

In connection with the publication of results from two independent research studies on ColdZyme, Enzymatica AB held a digital press conference on March 5, 2025.

The press conference is available for replay at the following link:

<https://creo-live.creomediamanager.com/eda7c0f6-7107-4d87-b409-82bdf2d58605>

Read the press release published 28 February here:

<https://www.enzymatica.com/media/press-releases/2025/new-independent-studies-show-that-coldzyme-addresses-the-root-cause-of-respiratory-infections-reducing-sick-days-and-symptoms/>

Link to the published article in *The Journal of Physiology*:

<https://physoc.onlinelibrary.wiley.com/doi/10.1113/JP288136>

For more information, contact:

Anja Tragardh, Corporate Communications, Enzymatica AB

Email: anja.tragardh@enzymatica.com

About Enzymatica

Enzymatica AB (publ) develops and markets products that treat and alleviate infections and symptoms in the upper airways. The best-selling product is ColdZyme®, an oral spray for colds and cold-like symptoms in the upper airways. The company's strategy is to continue growing by strengthening its position in existing markets and expanding into additional geographic markets through collaborations with established partners under their brands in the cold remedy market.

The company is headquartered in Lund and is listed on Nasdaq First North Growth Market. The Certified Adviser is Carnegie Investment Bank AB (publ).

For more information, visit www.enzymatica.se